The utility of the 21-gene Oncotype DX Breast Recurrence Score® assay in node-negative breast cancer patients - the final analysis of the Polish real-life survey PONDx.
| Title: | The utility of the 21-gene Oncotype DX Breast Recurrence Score® assay in node-negative breast cancer patients - the final analysis of the Polish real-life survey PONDx. |
|---|---|
| Authors: | Jarząb M; Breast Cancer Centre, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland.; Litwiniuk M; Department of Clinical Oncology and Immuno-oncology, Greater Poland Cancer Centre, Poznań, Poland.; Department of Cancer Pathology and Prevention, Poznań University of Medical Sciences, Poznań, Poland.; Innis P; Exact Sciences Corporation, Redwood City, CA, USA.; Łacko A; Lower Silesian Oncology Centre, Medical University of Wrocław, Wrocław, Poland.; Enderle G; Exact Sciences International GmbH, Baar, Switzerland.; Czartoryska-Arłukowicz B; M. Skłodowska-Curie Bialystok Oncology Centre, Białystok, Poland.; Talerczyk M; West Pomeranian Oncology Centre in Szczecin, Szczecin, Poland.; Streb J; Department of Oncology, Jagiellonian University Medical College, Kraków, Poland.; Department of Oncology, Krakow University Hospital, Kraków, Poland.; Wysocki P; Department of Oncology, Jagiellonian University Medical College, Kraków, Poland.; Department of Oncology, Krakow University Hospital, Kraków, Poland.; Suchodolska G; Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland.; Szymanowski B; Department of Oncology, Military Institute of Medicine - National Research Institute, Warsaw, Poland.; Duchnowska R; Department of Oncology, Military Institute of Medicine - National Research Institute, Warsaw, Poland. |
| Source: | Contemporary oncology (Poznan, Poland) [Contemp Oncol (Pozn)] 2024; Vol. 28 (3), pp. 245-252. Date of Electronic Publication: 2024 Oct 15. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Termedia Country of Publication: Poland NLM ID: 101233223 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1428-2526 (Print) Linking ISSN: 14282526 NLM ISO Abbreviation: Contemp Oncol (Pozn) Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: Poznań : Termedia |
| Abstract: | Introduction: Breast cancer (BC) is among the most frequently diagnosed malignant tumours in females. The optimal treatment of early HR+, HER2-, and lymph node-negative (N0) BC remains challenging. Since individual assessment of recurrence risk and expected benefits from adjuvant chemotherapy (CT) based on clinicopathological features alone appear inadequate, gene expression profiling tests have been developed. This study aimed to evaluate the impact of Oncotype DX Breast Recurrence Score® (Oncotype DX Breast RS) test results on physicians' decisions concerning adjuvant CT in the Polish population.; Material and Methods: The PONDx survey investigated the real-life use of Oncotype DX Breast RS in 204 pa- tients with HR+, HER2-, N0 BC in 8 clinical reference centres in Poland. Data on clinicopathological features and changes in treatment based on the Oncotype DX Breast RS test were collected.; Results: Chemotherapy plus endocrine therapy (ET) was initially recommended in 44.8% and ET alone in 55.2% of patients. After the introduction of recurrence score results, the recommendation for CT decreased significantly: relative reduction of 25.5% (95% CI: 11.7-52.3) and absolute reduction of 11.4% (95% CI: 1.9-21.0). Among patients initially recommended for CT, treatment was de-escalated in 62.2%; conversely, among patients initially recommended for ET alone, 29.7% were escalated to CT after testing. The relative reduction was especially pronounced in post-menopausal patients (29.6%) and in those with lobular BC (42.9%).; Conclusions: The Oncotype DX Breast RS result significantly influenced treatment decisions, with 44.3% of patients changing treatment, thus avoiding overtreatment or undertreatment. The Oncotype DX Breast RS test improves patient management and increases physician confidence in treatment recommendations.; (Copyright © 2024 Termedia.) |
| Competing Interests: | None. |
| References: | N Engl J Med. 2004 Dec 30;351(27):2817-26. (PMID: 15591335); Curr Oncol. 2023 Mar 06;30(3):3079-3090. (PMID: 36975446); Lancet. 2004 Sep 4-10;364(9437):858-68. (PMID: 15351193); Lancet. 2012 Feb 4;379(9814):432-44. (PMID: 22152853); J Clin Oncol. 2014 Oct 10;32(29):3307-29. (PMID: 25185096); N Engl J Med. 2018 Jul 12;379(2):111-121. (PMID: 29860917); N Engl J Med. 2010 Jun 3;362(22):2053-65. (PMID: 20519679); PLoS One. 2017 Oct 10;12(10):e0184360. (PMID: 29016607); Breast Cancer Res Treat. 2015 Oct;153(3):573-82. (PMID: 26364296); Cancer Treat Res Commun. 2022;31:100519. (PMID: 35093682); Ann Surg Oncol. 2018 Feb;25(2):512-519. (PMID: 29159748); Breast Cancer Res. 2021 Jul 17;23(1):74. (PMID: 34274003); N Engl J Med. 2021 Dec 16;385(25):2336-2347. (PMID: 34914339); Oncologist. 2018 Jul;23(7):768-775. (PMID: 29371476); Oncologist. 2019 Nov;24(11):1424-1431. (PMID: 31152079); Breast Cancer Res. 2006;8(3):R25. (PMID: 16737553); Health Technol Assess. 2019 Jun;23(30):1-328. (PMID: 31264581); J Clin Oncol. 2006 Aug 10;24(23):3726-34. (PMID: 16720680); Cancers (Basel). 2021 Aug 09;13(16):. (PMID: 34439158); Int J Cancer. 2019 Aug 15;145(4):882-893. (PMID: 30653259); J Clin Oncol. 2010 Apr 10;28(11):1829-34. (PMID: 20212256); NPJ Breast Cancer. 2021 May 5;7(1):47. (PMID: 33953182); Clin Breast Cancer. 2022 Jan;22(1):e74-e79. (PMID: 34690081); J Womens Health (Larchmt). 2011 Aug;20(8):1135-9. (PMID: 21675875); Breast Care (Basel). 2024 Feb;19(1):27-33. (PMID: 38384494); Breast Cancer Res Treat. 2023 Aug;201(1):1-3. (PMID: 37310541); J Comp Eff Res. 2019 Apr;8(5):289-304. (PMID: 30663337); Eur J Cancer. 2013 Jul;49(11):2469-75. (PMID: 23611660); Oncology (Williston Park). 2015 Nov;29(11):828-38. (PMID: 26573062); Diagnostics (Basel). 2023 Dec 31;14(1):. (PMID: 38201405); Eur J Surg Oncol. 2017 May;43(5):909-920. (PMID: 27639633); Front Oncol. 2020 Oct 30;10:1583. (PMID: 33194568); JAMA Oncol. 2020 Mar 1;6(3):367-374. (PMID: 31566680); Mol Diagn Ther. 2020 Oct;24(5):621-632. (PMID: 32613290); Breast. 2019 Apr;44:39-45. (PMID: 30634106); Breast Cancer Res Treat. 2022 Jan;191(2):477-480. (PMID: 34817748); N Engl J Med. 2019 Jun 20;380(25):2395-2405. (PMID: 31157962); Breast Cancer Res Treat. 2016 Jun;157(3):427-35. (PMID: 27206678); Breast Cancer Res Treat. 2013 Jun;139(2):539-52. (PMID: 23674192); Breast Cancer Res Treat. 2015 Oct;153(3):477-91. (PMID: 26341751); Breast J. 2017 Nov;23(6):677-686. (PMID: 28097781); Nat Rev Dis Primers. 2019 Jan 7;5(1):1. (PMID: 30617281); Oncologist. 2022 Oct 1;27(10):822-831. (PMID: 35830543) |
| Contributed Indexing: | Keywords: Oncotype DX Breast Recurrence Score®; adjuvant chemotherapy; breast cancer; real life study |
| Entry Date(s): | Date Created: 20241108 Latest Revision: 20241114 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC11538975 |
| DOI: | 10.5114/wo.2024.144222 |
| PMID: | 39512534 |
| Database: | MEDLINE |
Journal Article